نتایج جستجو برای: alk kinase

تعداد نتایج: 231548  

2013
Fredika M Robertson Emanuel F Petricoin III Steven J Van Laere Francois Bertucci Khoi Chu Sandra V Fernandez Zhaomei Mu Katherine Alpaugh Jianming Pei Rita Circo Julia Wulfkuhle Zaiming Ye Kimberly M Boley Hui Liu Ricardo Moraes Xuejun Zhang Ruggero DeMaria Sanford H Barsky Guoxian Sun Massimo Cristofanilli

Although Inflammatory Breast Cancer (IBC) is recognized as the most metastatic variant of locally advanced breast cancer, the molecular basis for the distinct clinical presentation and accelerated program of metastasis of IBC is unknown. Reverse phase protein arrays revealed activation of the receptor tyrosine kinase, anaplastic lymphoma kinase (ALK) and biochemically-linked downstream signalin...

Journal: :Cancer research 2012
Hong Ren Zhi-Ping Tan Xin Zhu Katherine Crosby Herbert Haack Jian-Min Ren Sean Beausoleil Albrecht Moritz Gregory Innocenti John Rush Yi Zhang Xin-Min Zhou Ting-Lei Gu Yi-Feng Yang Michael J Comb

Ovarian cancer is the leading cause of death from gynecologic cancer. Improvement in the clinical outcome of patients is likely to be achieved by the identification of molecular events that underlie the oncogenesis of ovarian cancer. Here we show that the anaplastic lymphoma kinase (ALK) is aberrantly activated in ovarian cancer. Using an unbiased and global phosphoproteomic approach, we profil...

Journal: :Expert opinion on therapeutic patents 2010
Karen L Milkiewicz Gregory R Ott

IMPORTANCE OF THE FIELD Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that belongs to the insulin receptor superfamily. Aberrant ALK activity has been implicated in the oncogenesis of human cancers as a fusion protein in anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, diffuse large B-cell lymphoma, systemic histiocytosis and NSCLC or through mutations in the...

2015
Jianya Zhou Jing Zheng Jing Zhao Yihong Sheng Wei Ding Jianying Zhou

A patient presenting with concomitant epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) translocation is rare. We report a non-small cell lung cancer (NSCLC) patient with concomitant ALK rearrangement and exon 19 (E746-A750del) EGFR mutation. The ALK rearrangement was confirmed not only in the primary tumor biopsy specimen, but also in the pleural effusion ce...

Journal: :Blood 2006
Mohamad Fawal Florence Armstrong Severine Ollier Henri Dupont Christian Touriol Bernard Monsarrat Georges Delsol Bernard Payrastre Dominique Morello

Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is a chimeric protein expressed in a subset of cases of anaplastic large cell lymphoma (ALCL) for which constitutive expression represents a key oncogenic event. The ALK signaling pathway is complex and probably involves functional redundancy between various signaling substrates of ALK. Despite numerous studies on signaling mediators, the molec...

Journal: :Cancer Imaging 2006
Fiona Kyle James Spicer

INTRODUCTION Anaplastic lymphoma kinase (ALK) and ROS1 rearrangements define important molecular subgroups of advanced non-small cell lung cancer (NSCLC). The identification of these genetic driver alterations created new potential for highly active therapeutic interventions. After discovery of ALK rearrangements in NSCLC, it was recognized that these confer sensitivity to ALK inhibition. Areas...

Ali Sadeghie-Tari Easa Jahanzad Fahimeh Asadi-Amoli Farnoosh Azadbakht, Mojgan Akbarzadeh-Jahromi

  Background and Objective: Inflammatory pseudotumor  is a lesion composed of proliferating spindle cells with mixed inflammatory infiltrates. Some authors have proposed the name inflammatory myofibroblastic tumor as a proper descriptive term rather than the vague inflammatory pseudotumor. The aim of this study was to verify the myofibroblastic origin of spindle cells in idiopathic orbital inf...

Journal: :Molecular cancer research : MCR 2015
M Ceccon L Mologni G Giudici R Piazza A Pirola D Fontana C Gambacorti-Passerini

UNLABELLED ALK is a tyrosine kinase receptor involved in a broad range of solid and hematologic tumors. Among 70% to 80% of ALK(+) anaplastic large cell lymphomas (ALCL) are caused by the aberrant oncogenic fusion protein NPM-ALK. Crizotinib was the first clinically relevant ALK inhibitor, now approved for the treatment of late-stage and metastatic cases of lung cancer. However, patients freque...

Journal: :Frontiers in bioscience 2015
Julie Bergalet Mohamad Fawal Dominique Morello Estelle Espinos

Extensive research has been carried out in the past two decades to provide insights into the molecular mechanisms by which the Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK) exerts its oncogenic effects. These studies led to the concept that NPM-ALK acts at the transcriptional level through the activation of several transcription factors downstream of many different signaling pathways inclu...

2011
Sen Zhang Frank Wang Jeffrey Keats Xiaotian Zhu Yaoyu Ning Scott D Wardwell Lauren Moran Qurish K Mohemmad Rana Anjum Yihan Wang Narayana I Narasimhan David Dalgarno William C Shakespeare Juan J Miret Tim Clackson Victor M Rivera

Activating gene rearrangements of anaplastic lymphoma kinase (ALK) have been identified as driver mutations in non-small-cell lung cancer, inflammatory myofibroblastic tumors, and other cancers. Crizotinib, a dual MET/ALK inhibitor, has demonstrated promising clinical activity in patients with non-small-cell lung cancer and inflammatory myofibroblastic tumors harboring ALK translocations. Inhib...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید